The newly named ThermoGenesis has moved from automated cell separation and cryostorage technologies into cell manufacturing tools and services for regenerative therapies
Photo as seen on company website
Cesca Therapeutics has announced that it will change its name to ThermoGenesis Holdings to better reflect its new strategic focus on cell manufacturing tools and services in the cell and gene therapy markets. In conjunction with the name change, the company will begin trading under the new Nasdaq ticker symbol, THMO.
ThermoGenesis has been a well-respected brand for automated cell separation and cryostorage technologies in the stem cell and cord blood industry for nearly three decades. In recent years, the company has successfully launched a series of new devices, including the CAR-TXpress cellular processing platform.
Recognising the potential of its proprietary technologies, the company is committed to further expanding the development of tools and services in the global cell and gene therapy market. The company has also decided to terminate its current clinical programmes in the regenerative medicine field in order to focus exclusively on becoming a preferred solution provider for the global cell and gene therapy market.
The company is committed to further expanding the development of tools and services in the global cell and gene therapy market
As part of this change, the company has most recently entered a definitive agreement with US-based HealthBanks Biotech to form a joint venture named ImmuneCyte Life Sciences to initiate immune cell banking services in the US using the CART-Xpress platform.
"ThermoGenesis will continue to take advantage of its proprietary technology in the automated cell processing field and focus on developing the next generation of CMO/CDMO services," said Dr Chris Xu, Chairman and CEO of the company. "Our name and ticker change reflect the company's streamlined business focus toward addressing critical unmet manufacturing needs in the global cell and gene therapy market.
Phil Coelho, the company's original Founder and Chief Technology Officer, said: "Our present focus will allow us to continue to be at the forefront to help drive future development of CAR-T cell therapeutics and other cell and gene therapy products and make them more accessible to the patients."